The fundraising environment has remained challenging but plenty of significant financing deals are getting done, sometimes with some creative structuring. The evolution of deal terms is often a reflection of the general risk appetite of investors and we want to take the pulse of the financing environment in the meeting.

Partnering deals with strategics has moved back to the forefront as a critical financing tool especially for platform companies. But not every partnering deal is the same and should reflect the strategic needs of both partners.

Last but not least, the M&A momentum has gained pace this year as big pharma is looking with growing urgency for assets late in their developmental stage. Interestingly, Europe has also seen several significant inbound M&A deals from Japanese corporates (eg. Orchard Therapeutics, Calliditas Therapeutics) – could this be a growing trend and are there particular deal features to consider?

This is our first Cooley Office Hour, where Tom Goodman from the London office and Brandon Fenn from their NY office will discuss the current landscape of deals in financing, partnering and M&A.